Philippe Moreau, MD, on Conclusions With VTd Plus Daratumumab in Newly Diagnosed Myeloma at ASCO 2021

Moreau discussed conclusions drawn from part 2 of the CASSIOPEIA trial and the need for further follow-up with bortezomib, thalidomide and dexamethasone plus maintenance daratumumab in newly diagnosed multiple myeloma.

At the 2021 American Society of Clinical Oncology (ASCO) Annual Meeting, CancerNetwork® sat down with Philippe Moreau, MD, of the University Hospital of Nantes, to discuss conclusions from part 2 of the phase 3 CASSIOPEIA trial (NCT02541383), which utilized daratumumab (Darzalex) maintenance therapy following treatment with bortezomib, thalidomide, and dexamethasone (VTd) in patients with newly diagnosed multiple myeloma. Moreau emphasized the need for a longer follow-up to validate these results.


We were able to update the results of part 1 [of the study]. The results are really clear from the first randomization with a very long follow-up now. Progression-free survival improved [in those who] received daratumumab up front during induction consolidation. [In order] to define the exact role of daratumumab in the maintenance setting, we need to have a long follow-up of the CASSIOPEIA trial, but also [for] the results of ongoing trials that are looking at daratumumab with lenalidomide [Revlimid; including] lenalidomide versus lenalidomide plus daratumumab. [It is possible that] the optimal strategy is the combination of daratumumab plus lenalidomide.


Moreau P & Sonneveld P. Daratumumab (DARA) maintenance or observation (OBS) after treatment with bortezomib, thalidomide and dexamethasone (VTd) with or without DARA and autologous stem cell transplant (ASCT) in patients (pts) with newly diagnosed multiple myeloma (NDMM): CASSIOPEIA Part 2. J Clin Oncol. 2021;39(suppl 15):8004. doi:10.1200/JCO.2021.39.15_suppl.8004